1
|
Lee M, Kaiser RE, Armstrong CD, Dukenik DB, Soong D, Elliott NS, Balise RR, Kobetz EN, Taylor J. EPR24-120: A Data-Driven Approach to Increase Lung Cancer Screening Rate in the Catchment Area of an NCI-Designated Cancer Center via Community Outreach and Engagement. J Natl Compr Canc Netw 2024; 22:EPR24-120. [PMID: 38580235 DOI: 10.6004/jnccn.2023.7168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2024]
Affiliation(s)
- Ming Lee
- 1University of Miami Miller School of Medicine, Miami, FL
| | | | | | | | - Deborah Soong
- 1University of Miami Miller School of Medicine, Miami, FL
| | | | | | - Erin N Kobetz
- 1University of Miami Miller School of Medicine, Miami, FL
| | - Justin Taylor
- 1University of Miami Miller School of Medicine, Miami, FL
| |
Collapse
|
2
|
Wong R, Soong D. Disparities in neighbourhood characteristics and 10-year dementia risk by nativity status. Epidemiol Psychiatr Sci 2024; 33:e7. [PMID: 38356391 PMCID: PMC10894703 DOI: 10.1017/s2045796024000076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/13/2023] [Revised: 12/27/2023] [Accepted: 01/21/2024] [Indexed: 02/16/2024] Open
Abstract
AIMS Prior research indicates that neighbourhood disadvantage increases dementia risk. There is, however, inconclusive evidence on the relationship between nativity and cognitive impairment. To our knowledge, our study is the first to analyse how nativity and neighbourhood interact to influence dementia risk. METHODS Ten years of prospective cohort data (2011-2020) were retrieved from the National Health and Aging Trends Study, a nationally representative sample of 5,362 U.S. older adults aged 65+. Cox regression analysed time to dementia diagnosis using nativity status (foreign- or native-born) and composite scores for neighbourhood physical disorder (litter, graffiti and vacancies) and social cohesion (know, help and trust each other), after applying sampling weights and imputing missing data. RESULTS In a weighted sample representing 26.9 million older adults, about 9.5% (n = 2.5 million) identified as foreign-born and 24.4% (n = 6.5 million) had an incident dementia diagnosis. Average baseline neighbourhood physical disorder was 0.19 (range 0-9), and baseline social cohesion was 4.28 (range 0-6). Baseline neighbourhood physical disorder was significantly higher among foreign-born (mean = 0.28) compared to native-born (mean = 0.18) older adults (t = -2.4, p = .02). Baseline neighbourhood social cohesion was significantly lower for foreign-born (mean = 3.57) compared to native-born (mean = 4.33) older adults (t = 5.5, p < .001). After adjusting for sociodemographic, health and neighbourhood variables, foreign-born older adults had a 51% significantly higher dementia risk (adjusted hazard ratio = 1.51, 95% CI = 1.19-1.90, p < .01). There were no significant interactions for nativity with neighbourhood physical disorder or social cohesion. CONCLUSIONS Our findings suggest that foreign-born older adults have higher neighbourhood physical disorder and lower social cohesion compared to native-born older adults. Despite the higher dementia risk, we observed for foreign-born older adults, and this relationship was not moderated by either neighbourhood physical disorder or social cohesion. Further research is needed to understand what factors are contributing to elevated dementia risk among foreign-born older adults.
Collapse
Affiliation(s)
- R. Wong
- Department of Public Health and Preventive Medicine, Norton College of Medicine, SUNY Upstate Medical University, Syracuse, NY, USA
- Department of Geriatrics, SUNY Upstate Medical University, Syracuse, NY, USA
| | - D. Soong
- Norton College of Medicine, SUNY Upstate Medical University, Syracuse, NY, USA
| |
Collapse
|
3
|
Soong D, Taylor J. New Targeted Therapy Combination Holds Promise to Untangle Hairy Cell Leukemia. NEJM Evid 2023; 2:EVIDe2300173. [PMID: 38320184 DOI: 10.1056/evide2300173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/08/2024]
Abstract
Hairy cell leukemia (HCL) is an uncommon B-cell neoplasm uniquely characterized by a high prevalence of the BRAFV600E mutation, which leads to constitutive activation of the mitogen-activated protein kinase (MAPK) pathway.1 In fact, the BRAFV600E point mutation is identified in nearly all cases of HCL; however, it is absent in HCL variant (vHCL) and rare in other B-cell neoplasms.2,3 Notably, in contrast to melanoma or other BRAF mutant solid tumors, HCL exhibits very few other mutations, potentially explaining the high response rates observed in patients treated with mutant BRAF-targeted agents, such as vemurafenib.
Collapse
Affiliation(s)
- Deborah Soong
- Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, Miami
| | - Justin Taylor
- Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, Miami
| |
Collapse
|
4
|
Davis JA, Rizzieri DA, Lane AA, Taylor J, Faisal MS, Vasu S, Soong D, Li H, Herbst A, Greenwell IB. Treatment patterns and outcomes of patients with CNS involvement of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Leuk Lymphoma 2022; 63:2757-2759. [DOI: 10.1080/10428194.2022.2090552] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- James A. Davis
- Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA
| | | | - Andrew A. Lane
- Medical Oncology, Dana Farber – Harvard Institute, Boston, MA, USA
| | - Justin Taylor
- University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USA
| | | | - Sumithira Vasu
- Division of Hematology, The Ohio State University, Columbus, OH, USA
| | - Deborah Soong
- University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USA
| | - Hong Li
- Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA
| | - Amanda Herbst
- Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA
| | - I. Brian Greenwell
- Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA
| |
Collapse
|
5
|
Montoya S, Soong D, Nguyen N, Affer M, Munamarty SP, Taylor J. Targeted Therapies in Cancer: To Be or Not to Be, Selective. Biomedicines 2021; 9:1591. [PMID: 34829820 PMCID: PMC8615814 DOI: 10.3390/biomedicines9111591] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2021] [Revised: 10/22/2021] [Accepted: 10/27/2021] [Indexed: 12/31/2022] Open
Abstract
Development of targeted therapies in recent years revealed several nonchemotherapeutic options for patients. Chief among targeted therapies is small molecule kinase inhibitors targeting key oncogenic signaling proteins. Through competitive and noncompetitive inhibition of these kinases, and therefore the pathways they activate, cancers can be slowed or completely eradicated, leading to partial or complete remissions for many cancer types. Unfortunately, for many patients, resistance to targeted therapies, such as kinase inhibitors, ultimately develops and can necessitate multiple lines of treatment. Drug resistance can either be de novo or acquired after months or years of drug exposure. Since resistance can be due to several unique mechanisms, there is no one-size-fits-all solution to this problem. However, combinations that target complimentary pathways or potential escape mechanisms appear to be more effective than sequential therapy. Combinations of single kinase inhibitors or alternately multikinase inhibitor drugs could be used to achieve this goal. Understanding how to efficiently target cancer cells and overcome resistance to prior lines of therapy became imperative to the success of cancer treatment. Due to the complexity of cancer, effective treatment options in the future will likely require mixing and matching these approaches in different cancer types and different disease stages.
Collapse
Affiliation(s)
| | | | | | | | | | - Justin Taylor
- Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, 1501 NW 10th Avenue, Miami, FL 33136, USA; (S.M.); (D.S.); (N.N.); (M.A.); (S.P.M.)
| |
Collapse
|
6
|
Soong D, Kumar P, Jatwani K, Park J, Dogan A, Taylor J. Hairy Cell Leukemia Masquerading as CD5+ Lymphoproliferative Disease: The Importance of BRAF V600E Testing in Diagnosis and Treatment. JCO Precis Oncol 2021; 5:PO.20.00518. [PMID: 34250418 PMCID: PMC8232835 DOI: 10.1200/po.20.00518] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2020] [Revised: 03/11/2021] [Accepted: 05/07/2021] [Indexed: 12/17/2022] Open
Affiliation(s)
- Deborah Soong
- Department of Medicine, University of Miami Miller School of Medicine, Miami, FL.,Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL
| | - Priyadarshini Kumar
- Hematopathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Karan Jatwani
- Department of Hospice and Palliative Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Jae Park
- Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Ahmet Dogan
- Hematopathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Justin Taylor
- Department of Medicine, University of Miami Miller School of Medicine, Miami, FL.,Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL
| |
Collapse
|
7
|
Greenwell IB, Davis J, Li H, Soong D, Taylor J, Lane AA, Rizzieri D. Outcomes of CNS involvement in blastic plasmacytoid dendritic cell neoplasm (BPDCN). J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.e19043] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e19043 Background: BPDCN is rare cancer commonly involving the skin and marrow. Tagraxofusp (Tag), a CD123 targeted therapy, was the first FDA approved drug for BPDCN in 2018. CNS involvement occurs in 10-60% of patients and CNS staging and prophylactic (ppx) practices are variable. The pivotal trial of Tag in BPDCN did not require CNS staging and excluded those patients with known CNS involvement. Here, we describe one of the largest cohorts of BPDCN patients with known CNS involvement, including patients treated with Tag. Methods: We collected data from 4 centers on patients with CNS involvement defined by LP or imaging with high clinical suspicion. Survival was estimated via the Kaplan-Meier method with other analyses being descriptive. Results: CNS involvement was identified in 11 patients. Median age was 74 (range 51–83) and 10 were male. 5 patients had CNS staging at initial diagnosis. At time of CNS involvement, 6/11 patients had neuro symptoms. Prior to diagnosis of CNS involvement, 5 received Tag and none received CNS ppx. Of 9 patients treated for their known CNS involvement (table), one received CNS directed systemic therapy, with all others being treated with intrathecal (IT) chemotherapy. All patients treated with 3 or more doses of IT chemotherapy cleared their CSF, and survived at least 6 months from the diagnosis of CNS involvement, including two patients (#5 and 8) with large burden CNS disease and neuro symptoms. Median survival from time of diagnosis of BPDCN was 13.8 months (2.7-35.5) and from time of diagnosis of CNS involvement was 6.0 months (0.1-25.7). Conclusions: Asymptomatic CNS involvement by BPDCN is common; routine staging and ppx should be considered at diagnosis. Tagraxofusp did not appear to prevent the development of CNS disease. IT therapy effectively cleared and controlled CNS involvement in a majority of patients. IT therapy may be sufficient to control CNS disease and IT prophylaxis should be considered, including in patients on CD123 targeting therapies. Our results provide new insights into BPDCN with CNS involvement and include patients treated with recently developed novel systemic therapies.[Table: see text]
Collapse
Affiliation(s)
| | - James Davis
- Medical University of South Carolina, Charleston, SC
| | - Hong Li
- Department of Public Health, College of Medicine, Medical University of South Carolina, Charleston, SC
| | | | | | | | | |
Collapse
|
8
|
Stanchina M, Soong D, Zheng-Lin B, Watts JM, Taylor J. Advances in Acute Myeloid Leukemia: Recently Approved Therapies and Drugs in Development. Cancers (Basel) 2020; 12:E3225. [PMID: 33139625 PMCID: PMC7692236 DOI: 10.3390/cancers12113225] [Citation(s) in RCA: 45] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2020] [Revised: 10/26/2020] [Accepted: 10/28/2020] [Indexed: 12/26/2022] Open
Abstract
Acute myeloid leukemia (AML) is a genetically heterogeneous malignancy comprised of various cytogenetic and molecular abnormalities that has notoriously been difficult to treat with an overall poor prognosis. For decades, treatment options were limited to either intensive chemotherapy with anthracycline and cytarabine-based regimens (7 + 3) or lower intensity regimens including hypomethylating agents or low dose cytarabine, followed by either allogeneic stem cell transplant or consolidation chemotherapy. Fortunately, with the influx of rapidly evolving molecular technologies and new genetic understanding, the treatment landscape for AML has dramatically changed. Advances in the formulation and delivery of 7 + 3 with liposomal cytarabine and daunorubicin (Vyxeos) have improved overall survival in secondary AML. Increased understanding of the genetic underpinnings of AML has led to targeting actionable mutations such as FLT3, IDH1/2 and TP53, and BCL2 or hedgehog pathways in more frail populations. Antibody drug conjugates have resurfaced in the AML landscape and there have been numerous advances utilizing immunotherapies including immune checkpoint inhibitors, antibody-drug conjugates, bispecific T cell engager antibodies, chimeric antigen receptor (CAR)-T therapy and the development of AML vaccines. While there are dozens of ongoing studies and new drugs in the pipeline, this paper serves as a review of the advances achieved in the treatment of AML in the last several years and the most promising future avenues of advancement.
Collapse
Affiliation(s)
- Michele Stanchina
- Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA; (M.S.); (D.S.)
| | - Deborah Soong
- Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA; (M.S.); (D.S.)
- Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL 33136, USA
| | - Binbin Zheng-Lin
- Department of Medicine, Icahn School of Medicine Mount Sinai West-Morningside, New York, NY 10025, USA;
| | - Justin M. Watts
- Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA;
| | - Justin Taylor
- Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA;
| |
Collapse
|
9
|
Abstract
Engineered camelid antibody multimers can potently block SARS-CoV-2 viral entry.
Collapse
Affiliation(s)
- Deborah Soong
- Departments of Pediatrics and Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Rachel Leeman
- Departments of Pediatrics and Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Asha Pillai
- Departments of Pediatrics and Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, USA
| |
Collapse
|
10
|
Saravia D, Basher F, Arora A, Soong D, Fanfan D, Cotta J, Lopes G. P2.06 Lung Cancer Driver Mutations and PD-L1 Expression in US Latino Patients with Advanced Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.09.169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
11
|
Kapustin A, Chatrou M, Drozdov I, Soong D, Furmanik M, Alvarez-Hernandez D, Sanchis P, Shroff R, Yin X, Skepper J, Mayr M, Reutelingsperger C, Schurgers L, Shanahan C. 192 MODULATED EXOSOME SECRETION BY VASCULAR SMOOTH MUSCLE CELLS IS A NOVEL REGULATORY MECHANISM OF VASCULAR CALCIFICATION. Heart 2013. [DOI: 10.1136/heartjnl-2013-304019.192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
12
|
Soong D, Shen M. Molecular theory of viscoelasticity for homogeneous block and graft copolymers. J MACROMOL SCI B 2006. [DOI: 10.1080/00222348008213123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- D. Soong
- a Department of Chemical Engineering , University of California Berkeley , California, 94720
| | - M. Shen
- a Department of Chemical Engineering , University of California Berkeley , California, 94720
| |
Collapse
|
13
|
Affiliation(s)
- D. Soong
- a Department of Chemical Engineering University of California Berkeley , California, 94720
| | - S. S. Shyu
- a Department of Chemical Engineering University of California Berkeley , California, 94720
- b Department of Chemical Engineering , National Central University , Chungli, Taiwan
| | - M. Shen
- a Department of Chemical Engineering University of California Berkeley , California, 94720
| |
Collapse
|
14
|
|